Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Electrostatic subframing and compressive-sensing video in transmission electron microscopy.

Reed BW, Moghadam AA, Bloom RS, Park ST, Monterrosa AM, Price PM, Barr CM, Briggs SA, Hattar K, McKeown JT, Masiel DJ.

Struct Dyn. 2019 Sep 23;6(5):054303. doi: 10.1063/1.5115162. eCollection 2019 Sep.

2.

First Human Imaging Studies with the EXPLORER Total-Body PET Scanner.

Badawi RD, Shi H, Hu P, Chen S, Xu T, Price PM, Ding Y, Spencer BA, Nardo L, Liu W, Bao J, Jones T, Li H, Cherry SR.

J Nucl Med. 2019 Mar;60(3):299-303. doi: 10.2967/jnumed.119.226498. Epub 2019 Feb 7.

3.

Evaluation of CyberKnife® Fiducial Tracking Limitations to Assist Targeting Accuracy: A Phantom Study with Fiducial Displacement.

Goldsmith C, Green MM, Middleton B, Cowley I, Robinson A, Plowman NP, Price PM.

Cureus. 2018 Oct 30;10(10):e3523. doi: 10.7759/cureus.3523.

4.

Magnetic Drug Delivery: Where the Field Is Going.

Price PM, Mahmoud WE, Al-Ghamdi AA, Bronstein LM.

Front Chem. 2018 Dec 11;6:619. doi: 10.3389/fchem.2018.00619. eCollection 2018. Review.

5.
6.

Designing for impact: identifying stakeholder-driven interventions to support recovery after major cancer surgery.

McMullen C, Nielsen M, Firemark A, Price PM, Nakatani D, Tuthill J, McMyn R, Odisho A, Meyers M, Shibata D, Gilbert S.

Support Care Cancer. 2018 Dec;26(12):4067-4076. doi: 10.1007/s00520-018-4276-0. Epub 2018 Jun 6.

7.

CyberKnife Radiosurgery of Skull-base Tumors: A UK Center Experience.

Wilson HP, Price PM, Ashkan K, Edwards A, Green MM, Cross T, Beaney RP, Davies R, Sibtain A, Plowman NP, Goldsmith C Dr.

Cureus. 2018 Mar 27;10(3):e2380. doi: 10.7759/cureus.2380.

8.

An effective deep-inspiration breath-hold radiotherapy technique for left-breast cancer: impact of post-mastectomy treatment, nodal coverage, and dose schedule on organs at risk.

Rice L, Goldsmith C, Green MM, Cleator S, Price PM.

Breast Cancer (Dove Med Press). 2017 Jun 14;9:437-446. doi: 10.2147/BCTT.S130090. eCollection 2017.

9.

Mimicking Cdk2 phosphorylation of Bcl-xL at Ser73 results in caspase activation and Bcl-xL cleavage.

Seng NS, Megyesi J, Tarcsafalvi A, Price PM.

Cell Death Discov. 2016;2. pii: 16001. Epub 2016 Feb 1.

10.

Cdk2 phosphorylation of Bcl-xL after stress converts it to a pro-apoptotic protein mimicking Bax/Bak.

Megyesi J, Tarcsafalvi A, Seng N, Hodeify R, Price PM.

Cell Death Discov. 2016;2. pii: 15066. Epub 2016 Jan 18.

11.

Deep inspiration breath-hold (DIBH) technique applied in right breast radiotherapy to minimize liver radiation.

Rice L, Harris S, Green MML, Price PM.

BJR Case Rep. 2015 May 11;1(2):20150038. doi: 10.1259/bjrcr.20150038. eCollection 2015.

12.

Increased expression of p21WAF1/CIP1 in kidney proximal tubules mediates fibrosis.

Megyesi J, Tarcsafalvi A, Li S, Hodeify R, Seng NS, Portilla D, Price PM.

Am J Physiol Renal Physiol. 2015 Jan 15;308(2):F122-30. doi: 10.1152/ajprenal.00489.2014. Epub 2014 Nov 26.

13.

Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study.

Rembielak AI, Jain P, Jackson AS, Green MM, Santorelli GR, Whitfield GA, Crellin A, Garcia-Alonso A, Radhakrishna G, Cullen J, Taylor MB, Swindell R, West CM, Valle J, Saleem A, Price PM.

Transl Oncol. 2014 Feb 1;7(1):55-64. eCollection 2014 Feb.

14.

Ultra staging to unmask the prescribing of adjuvant therapy in cancer patients: the future opportunity to image micrometastases using total-body 18F-FDG PET scanning.

Price PM, Badawi RD, Cherry SR, Jones T.

J Nucl Med. 2014 Apr;55(4):696-7. doi: 10.2967/jnumed.113.133892. Epub 2014 Mar 6. No abstract available.

15.

Proximal tubule PPARα attenuates renal fibrosis and inflammation caused by unilateral ureteral obstruction.

Li S, Mariappan N, Megyesi J, Shank B, Kannan K, Theus S, Price PM, Duffield JS, Portilla D.

Am J Physiol Renal Physiol. 2013 Sep 1;305(5):F618-27. doi: 10.1152/ajprenal.00309.2013. Epub 2013 Jun 26.

16.

Gender differences control the susceptibility to ER stress-induced acute kidney injury.

Hodeify R, Megyesi J, Tarcsafalvi A, Mustafa HI, Hti Lar Seng NS, Price PM.

Am J Physiol Renal Physiol. 2013 Apr 1;304(7):F875-82. doi: 10.1152/ajprenal.00590.2012. Epub 2013 Jan 30.

17.

How Kaiser Permanente uses video ethnography of patients for quality improvement, such as in shaping better care transitions.

Neuwirth EB, Bellows J, Jackson AH, Price PM.

Health Aff (Millwood). 2012 Jun;31(6):1244-50. doi: 10.1377/hlthaff.2012.0134.

PMID:
22665836
18.

A possible mechanism of renal cell death after ischemia/reperfusion.

Price PM, Hodeify R.

Kidney Int. 2012 Apr;81(8):720-1. doi: 10.1038/ki.2011.495.

19.

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.

Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani AR, Rustin GJ.

Clin Cancer Res. 2012 Mar 1;18(5):1415-25. doi: 10.1158/1078-0432.CCR-11-2414. Epub 2012 Jan 10.

20.

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients.

Saleem A, Matthews JC, Ranson M, Callies S, André V, Lahn M, Dickinson C, Prenant C, Brown G, McMahon A, Talbot DC, Jones T, Price PM.

Theranostics. 2011;1:290-301. Epub 2011 Jun 1.

21.

Positron emission tomography imaging approaches for external beam radiation therapies: current status and future developments.

Price PM, Green MM.

Br J Radiol. 2011 Dec;84 Spec No 1:S19-34. doi: 10.1259/bjr/21263014. Epub 2011 Mar 22. Review.

22.

Cdk2-dependent phosphorylation of p21 regulates the role of Cdk2 in cisplatin cytotoxicity.

Hodeify R, Tarcsafalvi A, Megyesi J, Safirstein RL, Price PM.

Am J Physiol Renal Physiol. 2011 May;300(5):F1171-9. doi: 10.1152/ajprenal.00507.2010. Epub 2011 Feb 16.

23.

Computed tomography overestimation of esophageal tumor length: Implications for radiotherapy planning.

Sillah K, Williams LR, Laasch HU, Saleem A, Watkins G, Pritchard SA, Price PM, West CM, Welch IM.

World J Gastrointest Oncol. 2010 Apr 15;2(4):197-204. doi: 10.4251/wjgo.v2.i4.197.

24.

VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.

Nagengast WB, Lub-de Hooge MN, Oosting SF, den Dunnen WF, Warnders FJ, Brouwers AH, de Jong JR, Price PM, Hollema H, Hospers GA, Elsinga PH, Hesselink JW, Gietema JA, de Vries EG.

Cancer Res. 2011 Jan 1;71(1):143-53. doi: 10.1158/0008-5472.CAN-10-1088. Epub 2010 Nov 17.

25.

Development and validation of a variance model for dynamic PET: uses in fitting kinetic data and optimizing the injected activity.

Walker MD, Matthews JC, Asselin MC, Watson CC, Saleem A, Dickinson C, Charnley N, Julyan PJ, Price PM, Jones T.

Phys Med Biol. 2010 Nov 21;55(22):6655-72. doi: 10.1088/0031-9155/55/22/005. Epub 2010 Oct 20.

PMID:
20962367
26.

Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer.

Jackson AS, Jain P, Watkins GR, Whitfield GA, Green MM, Valle J, Taylor MB, Dickinson C, Price PM, Saleem A.

Clin Oncol (R Coll Radiol). 2010 Sep;22(7):570-7. doi: 10.1016/j.clon.2010.06.007. Epub 2010 Jul 21.

PMID:
20650619
27.

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.

Lunt SJ, Cawthorne C, Ali M, Telfer BA, Babur M, Smigova A, Julyan PJ, Price PM, Stratford IJ, Bloomer WD, Papadopoulou MV, Williams KJ.

Br J Cancer. 2010 Jul 13;103(2):201-8. doi: 10.1038/sj.bjc.6605753. Epub 2010 Jun 29.

28.

Chronic kidney disease and GWAS: "the proper study of mankind is man".

Price PM, Hirschhorn K, Safirstein RL.

Cell Metab. 2010 Jun 9;11(6):451-2. doi: 10.1016/j.cmet.2010.05.009.

29.

Protection of cisplatin cytotoxicity by an inactive cyclin-dependent kinase.

Hodeify R, Megyesi J, Tarcsafalvi A, Safirstein RL, Price PM.

Am J Physiol Renal Physiol. 2010 Jul;299(1):F112-20. doi: 10.1152/ajprenal.00151.2010. Epub 2010 May 5.

30.

A role for novel cell-cycle proteins in podocyte biology.

Price PM.

Kidney Int. 2010 Apr;77(8):660-1. doi: 10.1038/ki.2009.562. Review.

31.

An efficient synthetic strategy for obtaining 4-methoxy carbon isotope labeled combretastatin A-4 phosphate and other Z-combretastatins.

Pettit GR, Minardi MD, Hogan F, Price PM.

J Nat Prod. 2010 Mar 26;73(3):399-403. doi: 10.1021/np9004486.

32.

Optimization of the injected activity in dynamic 3D PET: a generalized approach using patient-specific NECs as demonstrated by a series of 15O-H2O scans.

Walker MD, Matthews JC, Asselin MC, Saleem A, Dickinson C, Charnley N, Julyan PJ, Price PM, Jones T.

J Nucl Med. 2009 Sep;50(9):1409-17. doi: 10.2967/jnumed.109.062679. Epub 2009 Aug 18.

33.

The cell cycle and acute kidney injury.

Price PM, Safirstein RL, Megyesi J.

Kidney Int. 2009 Sep;76(6):604-13. doi: 10.1038/ki.2009.224. Epub 2009 Jun 17. Review.

34.

Assessment of bladder motion for clinical radiotherapy practice using cine-magnetic resonance imaging.

McBain CA, Khoo VS, Buckley DL, Sykes JS, Green MM, Cowan RA, Hutchinson CE, Moore CJ, Price PM.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):664-71. doi: 10.1016/j.ijrobp.2008.11.040. Epub 2009 May 25.

PMID:
19473781
35.

Impact of Single pMOSFET Dielectric Degradation on NAND Circuit Performance.

Estrada D, Ogas ML, Southwick RG, Price PM, Baker RJ, Knowlton WB.

Microelectron Reliab. 2008 Mar;48(3):354-363.

36.

A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.

Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EO.

Cancer Res. 2009 Jan 1;69(1):120-7. doi: 10.1158/0008-5472.CAN-08-2356.

37.

Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure.

Saleem A, Price PM.

Clin Cancer Res. 2008 Dec 15;14(24):8184-90. doi: 10.1158/1078-0432.CCR-08-1324.

38.

Cytoplasmic initiation of cisplatin cytotoxicity.

Yu F, Megyesi J, Price PM.

Am J Physiol Renal Physiol. 2008 Jul;295(1):F44-52. doi: 10.1152/ajprenal.00593.2007. Epub 2008 Apr 9.

39.

Hypoxia-associated markers in gastric carcinogenesis and HIF-2alpha in gastric and gastro-oesophageal cancer prognosis.

Griffiths EA, Pritchard SA, McGrath SM, Valentine HR, Price PM, Welch IM, West CM.

Br J Cancer. 2008 Mar 11;98(5):965-73. doi: 10.1038/sj.bjc.6604210. Epub 2008 Feb 19.

40.

Activation and involvement of p53 in cisplatin-induced nephrotoxicity.

Wei Q, Dong G, Yang T, Megyesi J, Price PM, Dong Z.

Am J Physiol Renal Physiol. 2007 Oct;293(4):F1282-91. Epub 2007 Aug 1.

41.

Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes.

Saleem A, Aboagye EO, Matthews JC, Price PM.

Cancer Chemother Pharmacol. 2008 Apr;61(5):865-73. Epub 2007 Jul 18.

PMID:
17639391
42.

Neurocognitive dysfunction post-cardiac surgery and the neuroprotective effects of erythropoietin.

Bhimji Z, Estabrooks L, Price PM.

Can J Cardiovasc Nurs. 2007;17(2):5-8; quiz 8-9, 5. Review.

PMID:
17583315
43.

Involvement of the CDK2-E2F1 pathway in cisplatin cytotoxicity in vitro and in vivo.

Yu F, Megyesi J, Safirstein RL, Price PM.

Am J Physiol Renal Physiol. 2007 Jul;293(1):F52-9. Epub 2007 Apr 25.

44.

Diabetes: caught in the Akt?

Price PM.

Kidney Int. 2007 May;71(9):839-41.

45.

Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.

Griffiths EA, Pritchard SA, McGrath SM, Valentine HR, Price PM, Welch IM, West CM.

Br J Cancer. 2007 May 7;96(9):1377-83. Epub 2007 Apr 17.

46.

Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas.

Griffiths EA, Pritchard SA, Valentine HR, Whitchelo N, Bishop PW, Ebert MP, Price PM, Welch IM, West CM.

Br J Cancer. 2007 Jan 15;96(1):95-103. Epub 2006 Dec 19.

47.

Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2.

Price PM, Yu F, Kaldis P, Aleem E, Nowak G, Safirstein RL, Megyesi J.

J Am Soc Nephrol. 2006 Sep;17(9):2434-42. Epub 2006 Aug 16.

48.

Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients.

Gupta N, Saleem A, Kötz B, Osman S, Aboagye EO, Phillips R, Vernon C, Wasan H, Jones T, Hoskin PJ, Price PM.

Clin Cancer Res. 2006 May 15;12(10):3115-23.

49.

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.

Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PM, Price PM, Zweit J; Cancer Research UK Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee.

J Natl Cancer Inst. 2006 May 3;98(9):580-98. Review.

PMID:
16670384
50.

Imaging vascular physiology to monitor cancer treatment.

Laking GR, West C, Buckley DL, Matthews J, Price PM.

Crit Rev Oncol Hematol. 2006 May;58(2):95-113. Epub 2006 Jan 4. Review.

PMID:
16387510

Supplemental Content

Loading ...
Support Center